Esther Z. G.
- Country
- Spain
- Department
- Cardiology
Research Overview
- Evaluation of Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: A Randomized, Double-blind, Placebo-controlled Study
- Evaluation of Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986435 in Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Evaluation of Candesartan Cilexetil Versus Placebo in Asymptomatic Genetic Carriers of Dilated Cardiomyopathy-Causing Variants
Data & Insights
Has run more than one trial at 97 of 200 partner sites.
Specializations
Cardiac Specialization
This investigator demonstrates particular expertise in treating hypertrophic cardiomyopathy, with specific focus on both obstructive and non-obstructive variants of the condition.
- Obstructive HCM with left ventricular outflow tract involvement
- Non-obstructive hypertrophic cardiomyopathy management
The investigator's work encompasses evaluation of novel therapeutic approaches for treating symptomatic cardiac conditions.
Clinical Assessment Focus
Primary areas of clinical investigation include patient-reported health outcomes and exercise capacity evaluation in cardiovascular conditions.
- Symptom assessment and physical limitation studies
- Exercise performance measurement
- Long-term therapeutic monitoring
The investigator specializes in comprehensive evaluation of cardiac therapeutic interventions over extended treatment periods.
Therapeutic Development
The investigator's work involves assessment of novel cardiac medications and their effects on cardiovascular function.
- Safety and tolerability evaluations
- Pharmacological intervention studies
- Therapeutic efficacy assessment
Their research includes evaluation of medication effects in symptomatic cardiac patients requiring targeted intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.